114 related articles for article (PubMed ID: 37095605)
1. Real-world treatment patterns and outcomes for patients with advanced melanoma treated with immunotherapy or targeted therapy.
Lee S; Bennett AV; Zhou X; Betof Warner A; Trogdon JG; Kent EE; Lund JL
Pharmacoepidemiol Drug Saf; 2023 Sep; 32(9):988-1000. PubMed ID: 37095605
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors retain effectiveness in older patients with cutaneous metastatic melanoma.
Howell AV; Gebregziabher M; Thiers BH; Paulos CM; Wrangle JM; Hunt KJ; Wallace K
J Geriatr Oncol; 2021 Apr; 12(3):394-401. PubMed ID: 33132048
[TBL] [Abstract][Full Text] [Related]
3. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
[TBL] [Abstract][Full Text] [Related]
4. First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma.
Wang X; Haaland B; Hu-Lieskovan S; Colman H; Holmen SL
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1419. PubMed ID: 34137219
[TBL] [Abstract][Full Text] [Related]
5. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting.
Cowey CL; Boyd M; Aguilar KM; Beeks A; Krepler C; Scherrer E
Cancer Med; 2020 Nov; 9(21):7863-7878. PubMed ID: 32871054
[TBL] [Abstract][Full Text] [Related]
6. Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study.
van Zeijl MCT; Haanen JBAG; Wouters MWJM; de Wreede LC; Jochems A; Aarts MJB; van den Berkmortel FWPJ; de Groot JWB; Hospers GAP; Kapiteijn EW; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van der Hoeven KJM; van den Eertwegh AJM
J Immunother; 2020 Oct; 43(8):256-264. PubMed ID: 32804914
[TBL] [Abstract][Full Text] [Related]
7. Real-world treatment patterns and overall survival in
Atkins MB; Julian C; Secrest MH; Lee J; Abajo-Guijarro AM; McKenna E
Future Oncol; 2022 Jun; 18(18):2233-2245. PubMed ID: 35441522
[TBL] [Abstract][Full Text] [Related]
8. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.
Kehl KL; Greenwald S; Chamoun NG; Manberg PJ; Schrag D
JAMA Netw Open; 2021 May; 4(5):e2111113. PubMed ID: 34019086
[TBL] [Abstract][Full Text] [Related]
9. First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland.
Cybulska-Stopa B; Pacholczak-Madej R; Kamińska-Winciorek G; Ziętek M; Czarnecka AM; Piejko K; Galus Ł; Ziółkowska B; Kieszko S; Kempa-Kamińska N; Calik J; Rolski J; Sałek-Zań A; Gajewska-Wicher K; Drosik-Kwaśniewska A; Rogala P; Kubiatowski T; Suwiński R; Mackiewicz J; Rutkowski P
Immunotherapy; 2021 Mar; 13(4):297-307. PubMed ID: 33353420
[No Abstract] [Full Text] [Related]
10. Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma.
Tang B; Mo J; Yan X; Duan R; Chi Z; Cui C; Si L; Kong Y; Mao L; Li S; Zhou L; Lian B; Wang X; Bai X; Xu H; Li C; Dai J; Guo J; Sheng X
Eur J Cancer; 2021 Oct; 156():83-92. PubMed ID: 34425407
[TBL] [Abstract][Full Text] [Related]
11. Survival outcomes in an older US population with advanced melanoma and central nervous system metastases: SEER-Medicare analysis.
Sadetsky N; Hernandez A; Wallick CJ; McKenna EF; Surinach A; Colburn DE
Cancer Med; 2020 Sep; 9(17):6216-6224. PubMed ID: 32667719
[TBL] [Abstract][Full Text] [Related]
12. Survival of advanced melanoma patients treated with immunotherapy and targeted therapy: A real-world study.
Yu SY; Mckavanagh D; McPherson I; Walpole E; Atkinson V; Hollingworth S
Pharmacoepidemiol Drug Saf; 2021 Oct; 30(10):1371-1379. PubMed ID: 33840147
[TBL] [Abstract][Full Text] [Related]
13. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
Samlowski W; Adajar C
BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688
[TBL] [Abstract][Full Text] [Related]
14. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
15. Association of Sociodemographic Factors With Immunotherapy Receipt for Metastatic Melanoma in the US.
Moyers JT; Patel A; Shih W; Nagaraj G
JAMA Netw Open; 2020 Sep; 3(9):e2015656. PubMed ID: 32876684
[TBL] [Abstract][Full Text] [Related]
16. Improvement of overall survival in stage IV melanoma patients during 2011-2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR).
Forschner A; Eichner F; Amaral T; Keim U; Garbe C; Eigentler TK
J Cancer Res Clin Oncol; 2017 Mar; 143(3):533-540. PubMed ID: 27878363
[TBL] [Abstract][Full Text] [Related]
17. Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study).
Nakamura Y; Namikawa K; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Fujimoto N; Kuwatsuka Y; Onishi M; Kaneko T; Onuma T; Umeda Y; Ogata D; Takahashi A; Otsuka M; Teramoto Y; Yamazaki N
ESMO Open; 2021 Dec; 6(6):100325. PubMed ID: 34839104
[TBL] [Abstract][Full Text] [Related]
18. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
[TBL] [Abstract][Full Text] [Related]
19. Real World Outcomes in Patients with Advanced Melanoma Treated in Alberta, Canada: A Time-Era Based Analysis.
Rigo R; Doherty J; Koczka K; Kong S; Ding PQ; Cheng T; Cheung WY; Monzon JG
Curr Oncol; 2021 Oct; 28(5):3978-3986. PubMed ID: 34677256
[TBL] [Abstract][Full Text] [Related]
20. Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma.
Pokorny R; McPherson JP; Haaland B; Grossmann KF; Luckett C; Voorhies BN; Sageser DS; Wallentine J; Tolman Z; Hu-Lieskovan S; Swami U
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33500258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
